Skip to content
OpenCapital
Get started

OS Therapies OSTX Earnings per common share - diluted (in dollars per share)

Earnings per common share - diluted (in dollars per share) at other companies

CTO
Citius Oncology, Inc.CTOR
-$0.27-145%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's earnings per common share - diluted (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's earnings per common share - diluted (in dollars per share)?
OS Therapies (OSTX) reported earnings per common share - diluted (in dollars per share) of -$0.27 in Q1 2026.
How has OS Therapies's earnings per common share - diluted (in dollars per share) changed year-over-year?
OS Therapies's earnings per common share - diluted (in dollars per share) decreased by 50.0% year-over-year, from -$0.18 to -$0.27.
What does earnings per common share - diluted (in dollars per share) mean?
This metric measures the portion of a company's profit allocated to each share of common stock, assuming all dilutive securities are converted. It serves as a key indicator of profitability while accounting for potential future dilution. Investors use this to assess the company's earnings potential on a fully diluted basis.